Niacin’s New Role: A Phase I Trial Shows Immune Modulation in Glioblastoma
A recent phase I dose-escalation clinical trial has investigated the effects of niacin on the immune system in patients with newly diagnosed glioblastoma, a highly aggressive brain tumor. Published in *Neurology Neuroimmunology & Neuroinflammation*, the study explores whether this common B vitamin can alter the body’s immune response within the challenging tumor microenvironment. The findings represent a novel approach to neuro-oncology, moving beyond traditional chemotherapy and radiation to target the complex interplay between the central nervous system and the immune system in neuroinflammatory and neurodegenerative conditions.
Why it might matter to you: This research directly intersects with key areas of neurology, including neuroinflammation and neuroimmunology, by testing a repurposed agent against a primary brain cancer. For professionals focused on neurodegeneration or neuropathology, understanding how to modulate the immune environment in the central nervous system could have broader implications for other conditions like multiple sclerosis or Alzheimer’s disease. The trial’s focus on immune responses offers a strategic insight into potential combinatorial therapies that target both the tumor and its supportive microenvironment.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
